Skip to main content
Erschienen in:

22.01.2024 | Review

The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis

verfasst von: Hadis Razmaray, Ehsan Nasiri, Pouya Vakilipour, Soroush Morsali, Afshin Moradi, Asal Ebrahimian, Sahel Rashidi, Reza Mosaddeghi-Heris, Saeed Sadigh-Eteghad, Amirreza Naseri

Erschienen in: Inflammopharmacology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Through the antioxidant and anti-inflammation pathways, melatonin is proposed as a safe and effective intervention in neurological diseases. This study aims to evaluate the effects of melatonin supplementation on the neurobehavioral and clinical outcomes in animal models of multiple sclerosis (MS).

Methods

This study was conducted following the PRISMA statement. Animal studies that reported the effects of melatonin in preclinical MS models, including the experimental autoimmune encephalomyelitis (EAE) and cuprizone model for demyelination are included in this study. A systematic search in PubMed, Web of Science, Embase, and Scopus up was conducted in April 2023. The collaborative Approach to Meta-Analysis and Review of Animal Experimental Studies (CAMARADES) critical appraisal tool was used for the quality assessment of the studies and the quantitative synthetizes were conducted using the comprehensive meta-analysis software.

Results

Out of 542 studies, finally 21 studies, including 14 studies in the EAE model and 7 studies of the toxic demyelination method with cuprizone were included. The route of administration was intraperitoneal in 18 studies, oral in 2 studies, and subcutaneous in 1 study. The quantitative synthesis of the EAE clinical severity scale was associated with significant differences (standardized mean difference [SDM]: − 2.52; − 3.61 to − 1.42; p value < 0.01). In subgroup analyses, the difference was statistically significant in the mouse subgroup (SMD: − 2.60; − 3.74 to − 1.46; p value < 0.01).

Discussion

This study encountered that melatonin may be associated with improved behavioral and cognitive outcomes of preclinical models of MS with acceptable safety profiles.

Funding

The research was supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 71005).
Literatur
Zurück zum Zitat Alghamdi BS, AboTaleb HA (2020) Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. J Integr Neurosci 19(2):229–237CrossRefPubMed Alghamdi BS, AboTaleb HA (2020) Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. J Integr Neurosci 19(2):229–237CrossRefPubMed
Zurück zum Zitat Álvarez-Sánchez N, Cruz-Chamorro I, López-González A, Utrilla JC, Fernández-Santos JM, Martínez-López A, Lardone PJ, Guerrero JM, Carrillo-Vico A (2015) Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance [Article]. Brain, Behavior Immunity 50:101–114. https://doi.org/10.1016/j.bbi.2015.06.021CrossRefPubMed Álvarez-Sánchez N, Cruz-Chamorro I, López-González A, Utrilla JC, Fernández-Santos JM, Martínez-López A, Lardone PJ, Guerrero JM, Carrillo-Vico A (2015) Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance [Article]. Brain, Behavior Immunity 50:101–114. https://​doi.​org/​10.​1016/​j.​bbi.​2015.​06.​021CrossRefPubMed
Zurück zum Zitat Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J, Valdelvira ME, Giraldo AI, Paz-Rojas E, Gascón F, Santamaría A, Agüera E, Túnez I (2022) Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis [Article]. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2022.103520CrossRefPubMed Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J, Valdelvira ME, Giraldo AI, Paz-Rojas E, Gascón F, Santamaría A, Agüera E, Túnez I (2022) Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis [Article]. Mult Scler Relat Disord. https://​doi.​org/​10.​1016/​j.​msard.​2022.​103520CrossRefPubMed
Zurück zum Zitat Ghareghani M, Dokoohaki S, Ghanbari A, Farhadi N, Zibara K, Khodadoust S, Parishani M, Ghavamizadeh M, Sadeghi H (2017) Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression [Article]. Clin Exp Pharmacol Physiol 44(1):52–61. https://doi.org/10.1111/1440-1681.12678CrossRefPubMed Ghareghani M, Dokoohaki S, Ghanbari A, Farhadi N, Zibara K, Khodadoust S, Parishani M, Ghavamizadeh M, Sadeghi H (2017) Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression [Article]. Clin Exp Pharmacol Physiol 44(1):52–61. https://​doi.​org/​10.​1111/​1440-1681.​12678CrossRefPubMed
Zurück zum Zitat Ghareghani M, Scavo L, Jand Y, Farhadi N, Sadeghi H, Ghanbari A, Mondello S, Arnoult D, Gharaghani S, Zibara K (2019) Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis. Front Pharmacol 10:147CrossRefPubMedPubMedCentral Ghareghani M, Scavo L, Jand Y, Farhadi N, Sadeghi H, Ghanbari A, Mondello S, Arnoult D, Gharaghani S, Zibara K (2019) Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis. Front Pharmacol 10:147CrossRefPubMedPubMedCentral
Zurück zum Zitat Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, Lee YJ, Shin T (2001) Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2(2):85–89CrossRefPubMed Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, Lee YJ, Shin T (2001) Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2(2):85–89CrossRefPubMed
Zurück zum Zitat Labunets I, Utko N, Toporova O, Pokholenko I, Panteleymonova T, Litoshenko Z, Butenko G (2021a) The effects of combined administration of human umbilical cord-derived multipotent mesenchymal stromal cells and melatonin or fibroblast growth factor-2 to aged mice with a toxic cuprizone model of demyelination [Article]. Cell Organ Transplant 9(1):4–11. https://doi.org/10.22494/cot.v9i1.116CrossRef Labunets I, Utko N, Toporova O, Pokholenko I, Panteleymonova T, Litoshenko Z, Butenko G (2021a) The effects of combined administration of human umbilical cord-derived multipotent mesenchymal stromal cells and melatonin or fibroblast growth factor-2 to aged mice with a toxic cuprizone model of demyelination [Article]. Cell Organ Transplant 9(1):4–11. https://​doi.​org/​10.​22494/​cot.​v9i1.​116CrossRef
Zurück zum Zitat Labunets IF, Utko NA, Toporova OK, Savosko SI, Pokholenko IO, Panteleymonova TN, Butenko GM (2021c) Melatonin and fibroblast growth factor-2 potentiate the effects of human umbilical cord multipotent mesenchymal stromal cells in mice with cuprizone-induced demyelination [Article]. Biopolym Cell 37(5):369–378. https://doi.org/10.7124/bc.000A62CrossRef Labunets IF, Utko NA, Toporova OK, Savosko SI, Pokholenko IO, Panteleymonova TN, Butenko GM (2021c) Melatonin and fibroblast growth factor-2 potentiate the effects of human umbilical cord multipotent mesenchymal stromal cells in mice with cuprizone-induced demyelination [Article]. Biopolym Cell 37(5):369–378. https://​doi.​org/​10.​7124/​bc.​000A62CrossRef
Zurück zum Zitat Mahmoodi M, Sedghy F, Jafarzadeh A (2020) Effect of Treatment with Thyme Extract on Urinary Levels of Melatonin in an Experimental Autoimmune Encephalomyelitis Mouse Model. Rep Biochem Mol Biol 8(4):407–412PubMedPubMedCentral Mahmoodi M, Sedghy F, Jafarzadeh A (2020) Effect of Treatment with Thyme Extract on Urinary Levels of Melatonin in an Experimental Autoimmune Encephalomyelitis Mouse Model. Rep Biochem Mol Biol 8(4):407–412PubMedPubMedCentral
Zurück zum Zitat Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://​doi.​org/​10.​1136/​bmj.​n71CrossRefPubMedPubMedCentral
Metadaten
Titel
The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis
verfasst von
Hadis Razmaray
Ehsan Nasiri
Pouya Vakilipour
Soroush Morsali
Afshin Moradi
Asal Ebrahimian
Sahel Rashidi
Reza Mosaddeghi-Heris
Saeed Sadigh-Eteghad
Amirreza Naseri
Publikationsdatum
22.01.2024
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 2/2024
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01414-7

Weitere Artikel der Ausgabe 2/2024

Inflammopharmacology 2/2024 Zur Ausgabe